Ucb SA banner

Intrinsic Value

The intrinsic value of Ucb SA (UNC) under the Base Case is 255 EUR per share. Compared with the current market price of 202 EUR, the stock appears Undervalued by 21% .

The intrinsic value is calculated using valuation multiples.

Do our valuations actually work? See backtest results .

UNC Intrinsic Value
€255
Undervaluation 21%
Intrinsic Value
Price €202

UNC is valued in line with its history. A discount of this size has been typical over the past 5 years.

Monitor UNC
Get notified when the price drops
Track Buy Zone
20% below Intrinsic Value €204
Get notified when the price drops into your buy zone
Intrinsic Value €255
Margin of Safety 20% €204
Current Price €202
Or choose another margin of safety
0% below Intrinsic Value
10% below Intrinsic Value
30% below Intrinsic Value
40% below Intrinsic Value
50% below Intrinsic Value
Custom
Alternatives to UNC

Fundamental Analysis

What Ucb Does

Pharmaceuticals Health Care

UCB SA is a Belgian biopharmaceutical company that develops and sells prescription medicines for people with serious immune and nervous system diseases. Its main products are treatments for conditions such as epilepsy, Parkinson’s-related movement problems, and immune-mediated disorders like psoriasis, arthritis, and other autoimmune diseases. The company spends heavily on research and clinical testing because its business depends on discovering, proving, and getting approval for new medicines.

Headquarters
Belgium BE
Employees
9 765
IPO date
Jan 2, 1987
Read the full company overview
View Company Overview
Financials
Efficiency

Earnings Waterfall
Ucb SA

Wall St Price Targets

Capital Returns

Competitive Landscape

Ownership

UCB Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one UNC stock?

The intrinsic value for Ucb SA (UNC) under the Base Case is 255 EUR.

Is UNC stock undervalued or overvalued?

Compared with the current market price of 202 EUR, the stock appears Undervalued by 21% .

Back to Top